MedTrace Logo

Expanded Access IND Administration of HBOC-201 in Patients With Severe Acute Anemia

NCT03633604 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-02-11

No results posted yet for this study

Summary

HBOC-201 provides an oxygen treatment bridge and can be used to eliminate, delay, or reduce the need for red blood cell transfusions in anemic patients

This is an expanded access IND protocol, and will provide treatment with HBOC-201 to severely anemic adults for whom blood is not an option

Conditions

  • Anemia Severe

Interventions

BIOLOGICAL

HBOC-201

Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.

Sponsors & Collaborators

  • HbO2 Therapeutics LLC

    collaborator INDUSTRY

  • Jonathan H. Waters

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633604 on ClinicalTrials.gov